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Crohn’s disease exacerbations can often be associated with bacterial infections causing gastroenteritis. We report a child who
experienced exacerbation of his Crohn’s disease associated with a positive stool culture for Edwardsiella tarda (E. tarda).
Endoscopy showed features of moderate inﬂammation similar to exacerbation of Crohn’s disease. (e patient was treated si-
multaneously with intravenous steroids and antibiotics, and his symptoms resolved.(is case report highlights the importance of
clinicians being able to promptly recognize and treat concurrent bacterial infections in Crohn’s disease exacerbations.
1. Introduction
Crohn’s disease (CD) is a lifelong chronic inﬂammatory
bowel disease (IBD) that aﬀects any part of the gastroin-
testinal (GI) tract. (ere are numerous pharmacological
agents available to treat CD and achieve disease remission:
steroids, immune modulators, and biologic therapies. De-
spite optimal immune-suppressive therapy, exacerbations of
CD can occur. (ese are typically treated with higher doses
of the aforementioned therapies, but they carry the risk of
opportunistic pathogens overwhelming the patient’s com-
promised immune system. CD exacerbations can also be
mimicked or caused by bacterial pathogens, most commonly
Clostridium diﬃcile [1]. We report the ﬁrst pediatric patient
with CD exacerbation secondary to E. tarda infection, a rare
human pathogen.
2. Case Report
An 8-year-old Caucasian boy presented in September 2013
with a history of frequent loose stools and bleeding per
rectum. He was diagnosed with CD and treated with
mesalamine (500mg t.i.d.) initially. Following a CD exac-
erbation in October 2014, he was treated with oral pred-
nisone regimen (40mg daily tapering course) and
azathioprine (50mg oral daily). In March 2015, inﬂiximab
(biologic) therapy (200mg IV) was initiated to optimize
disease control. InMay 2015, the patient was admitted to our
institution for exacerbation of CD and C. diﬃcile colitis. He
was treated with vancomycin (350mg oral q.i.d.) and
metronidazole (400mg IVq8h) for C. diﬃcile infection.
(e patient developed another CD ﬂare up 3 months
later and was reviewed urgently in our outpatient clinic. He
was experiencing abdominal pain daily and approximately 7
loose, bloody bowel movements per day and weight loss.(e
patient most likely ingested contaminated ﬁsh prior to the
onset of illness, but his close family members were well. No
history of recent foreign travel. (e patient was treated
empirically for a possible recurrence of C. diﬃcile infection
with a 10-day course of vancomycin (375mg oral q.i.d.) and
metronidazole (250mg oral t.i.d.). A repeat stool culture and
C. diﬃcile toxin was ordered at this visit.
(ree days into treatment for C. diﬃcile, his clinical status
was getting worse. He had nausea, intermittent nonbilious
vomiting, loose bloody stools, and poor appetite. He lost 8
pounds (10% weight loss) with signiﬁcant lethargy. (e
worsening clinical status resulted in a hospital admission at
his local hospital. (e patient was started on methylpred-
nisolone (40mg IV daily) for a CD ﬂare up and continued on
vancomycin and metronidazole. It was subsequently
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determined that he had a positive stool culture for E. tarda but
no evidence of C. diﬃcile. He continued to be unwell with a
fever (temperature 38.2°C), loose stools, and tachycardia (HR
112). He had mild diﬀuse tenderness in the lower quadrants.
In view of his immune-compromised state and risk of bac-
terial translocation which may set him up for bacteremia, we
transferred him to our tertiary centre. He was reviewed by the
Pediatric Infectious Diseases team, and blood cultures were
drawn prior to commencing intravenous ampicillin (1250mg
IV q6 hours). (erapy for C. diﬃcile was continued as was
steroid therapy. His blood investigations conﬁrmed leuko-
cytosis (25.5×109 L) with neutrophilia (18.7×109 L) and
thrombocytosis (746×109 L). (e CRP was mildly elevated
(16mgL). Ultrasound imaging did not reveal any intra-
abdominal abscesses. Endoscopy (Figures 1 and 2) and his-
topathology showed evidence of chronic active gastritis and
colitis. Once blood cultures were negative, he was switched to
oral amoxicillin (1000mg t.i.d.). He had gradual clinical
improvement and was discharged on a tapering regimen of
prednisone 12 days later. Repeat stool culture was negative.
(a) (b)
Figure 1: Upper endoscopy images: the stomach demonstrates multiple aphthous ulcerations, nodularity, friability, and erythema (typical of
Crohn’s).
(a) (b)
Figure 2: Lower endoscopy images: the colon shows diﬀuse moderate inﬂammation with ulcerations, mucosal edema, friability, cobble-
stoning, and pseudopolyp formation indistinguishable from Crohn’s disease.
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3. Discussion
(ere is a global rise in the incidence of inﬂammatory bowel
diseases (IBDs). (e etiology of IBD is not well understood;
however, it has been postulated that infectious gastroen-
teritis may be a precipitating or exacerbating factor [2]. CD
patients have been found to have higher concentrations of
proinﬂammatory bacteria like bacteroides, eubacteria, and
peptostreptococcus and reduced concentrations of pro-
tective biﬁdobacterial [3]. Synchronous enteric infections
occur in 10.5–20% of IBD relapses [4]. Immunosuppressed
patients with suspected CD ﬂare who are only treated for the
exacerbation run the risk of invasive infections with op-
portunistic bacteria. Since there may be a delay between
stool collection and microbiology results, it is important for
clinicians to always consider the possibility of concurrent
bacterial infections and institute appropriate therapy
promptly.
E. tarda is a Gram-negative, facultative anaerobic, rod-
shaped bacterium that belongs to the Enterobacteriaceae
family. E. tarda is isolated from fresh or brackish water and
can also be found in reptiles, eels, or catﬁshes [5]. Turtles and
snakes also act as reservoirs. Humans acquire the infection
through exposure to fresh water and marine environments
containing the bacteria or by eating raw ﬁsh [6]. While E.
tarda is relatively rare, occurring in less than 5% of people, it
can cause invasive infections like gastroenteritis, soft tissue
infections, septicemia, hepatobiliary infections, meningitis,
peritonitis, osteomyelitis, endocarditis, tubo-ovarian ab-
scess, and salpingitis with signiﬁcant mortality (22.7%) [7].
(e most common presentation is gastroenteritis of varying
severity with nausea, vomiting, abdominal cramping, fever,
bloody diarrhea, colonic ulcerations, and pseudomembranes
[6–8]. (e mortality rate of E tarda infection is high in
immune-compromised hosts (about 50%) and should be
treated as a life-threatening infection [6]. (e organism is
susceptible to beta-lactams such as ampicillin, cephalo-
sporins, and tazobactam as well as quinolones, nitro-
furantoin, and gentamicin [9].
To our knowledge, this is the second documented case of
a CD ﬂare with E. tarda [10] and the ﬁrst in a pediatric
patient. We successfully treated our patient with IV Am-
picillin and oral amoxicillin with complete recovery. (is
report underscores the value of performing a rigorous stool
culture in all patients presenting with exacerbations of IBD.
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